"Lymphoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A general term for various neoplastic diseases of the lymphoid tissue.
| Descriptor ID |
D008223
|
| MeSH Number(s) |
C04.557.386 C15.604.515.569 C20.683.515.761
|
| Concept/Terms |
Lymphoma- Lymphoma
- Lymphomas
- Sarcoma, Germinoblastic
- Germinoblastic Sarcoma
- Germinoblastic Sarcomas
- Sarcomas, Germinoblastic
- Reticulolymphosarcoma
- Reticulolymphosarcomas
- Germinoblastoma
- Germinoblastomas
- Lymphoma, Malignant
- Lymphomas, Malignant
- Malignant Lymphoma
- Malignant Lymphomas
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma".
This graph shows the total number of publications written about "Lymphoma" by people in this website by year, and whether "Lymphoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2006 | 2 | 0 | 2 |
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 2 | 0 | 2 |
| 2022 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoma" by people in Profiles.
-
?c cytokine-aided crosstalk between dendritic cells and natural killer cells together with doxorubicin induces a healer response in experimental lymphoma by downregulating FOXP3 and programmed cell death protein 1. Cytotherapy. 2022 Dec; 24(12):1232-1244.
-
Nanomedicine as a magic bullet for combating lymphoma. J Control Release. 2022 07; 347:211-236.
-
Beyond CD19 CAR-T cells in lymphoma. Curr Opin Immunol. 2022 02; 74:46-52.
-
Targeting PD-1 in CD8+ T Cells with a Biomimetic Bilirubin-5-fluoro-2-deoxyuridine-Bovine Serum Albumin Nanoconstruct for Effective Chemotherapy against Experimental Lymphoma. Mol Pharm. 2021 05 03; 18(5):2053-2065.
-
In Regard to Wong et al. Int J Radiat Oncol Biol Phys. 2020 12 01; 108(5):1395-1396.
-
Studies on interaction potency model based on drug synergy and therapeutic potential of triple stimuli-responsive delivery of doxorubicin and 5-fluoro-2-deoxyuridine against lymphoma using disulfide-bridged cysteine over mesoporous silica nanoparticles. J Mater Chem B. 2020 02 21; 8(7):1411-1421.
-
Essential role of TNF-a in gamma c cytokine aided crosstalk between dendritic cells and natural killer cells in experimental murine lymphoma. Int Immunopharmacol. 2020 Jan; 78:106031.
-
Fear of cancer recurrence in lymphoma survivors: A descriptive study. J Psychosoc Oncol. 2020 May-Jun; 38(3):251-271.
-
Protective and recuperative effects of 3-bromopyruvate on immunological, hepatic and renal homeostasis in a murine host bearing ascitic lymphoma: Implication of niche dependent differential roles of macrophages. Biomed Pharmacother. 2018 Mar; 99:970-985.
-
Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. Biol Blood Marrow Transplant. 2018 03; 24(3):486-493.